Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer
April 27 2010 - 7:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the
appointment of Charles Morris, MB ChB, MRCP, as executive vice
president, chief medical officer, effective today. In his position,
Dr. Morris will lead the Company’s clinical development functions,
including clinical operations, medical affairs, regulatory and
biometrics.
“We are delighted to welcome Charlie to Allos,” said Paul L.
Berns, president and chief executive officer of Allos Therapeutics.
“Charlie’s extensive oncology drug development experience and
demonstrated track record of gaining international regulatory
approvals, as well as leading research and development teams, will
be extremely valuable as we continue to advance our prioritized
product development and commercialization plan for FOLOTYN.”
Dr. Morris said, “Allos has built a great foundation with the
approval of FOLOTYN for patients with relapsed or refractory
peripheral T-cell lymphoma. I look forward to working with my
colleagues to make a difference in the lives of people around the
world, as we work towards expanding FOLOTYN’s reach outside the
U.S. and investigate its clinical utility in other hematologic
cancers and solid tumor indications.”
Dr. Morris brings to Allos more than fifteen years of medical
and international biopharmaceutical research and development
experience. He joined Cephalon, Inc. in 2007 and most recently
served as vice president worldwide clinical research responsible
for leading a large clinical research group focused on medical
science, clinical pharmacology, clinical operations, medical
writing, biometrics and biostatistics focused on Cephalon’s
oncology, immunology and neuroscience development portfolios. His
significant contributions helped Cephalon achieve the first
oncology drug approvals for TREANDA® (bendamustine HCI) for chronic
lymphocytic leukemia (CLL) and B-cell non-Hodgkin’s lymphoma (NHL).
Prior to Cephalon, Dr. Morris spent the majority of his career at
AstraZeneca Pharmaceuticals (formerly Zeneca Pharmaceuticals),
where he most recently served as vice president clinical
development projects, oncology. He held a number of leadership
roles during his tenure with AstraZeneca, including leading the
clinical aspects of the company’s successful new drug application
submission for FASLODEX® (fulvestrant) for metastatic breast
cancer, supporting marketed products for breast and prostate
cancers, and later providing oversight for the clinical development
of all late stage pipeline and marketed products. Dr. Morris
received Degrees of Bachelor of Medicine and Bachelor of Surgery,
Degree of Bachelor of Medical Science in Clinical Pharmacology and
Therapeutics from the Sheffield University Medical School, United
Kingdom, and is a member of the Royal College of Physicians of
London.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
This press release contains
forward-looking statements that involve significant risks and
uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2009 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. All
forward-looking statements are based on information currently
available to the Company on the date thereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
these presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Sep 2023 to Sep 2024